Jianchun C. Duan

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 160 publications

Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.

Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 16, 2026

Reshaping immunotherapy sequencing strategy: equivalent survival with induction plus consolidation vs. consolidation-only strategy in unresectable stage III NSCLC.

Reshaping immunotherapy sequencing strategy: equivalent survival with induction plus consolidation vs. consolidation-only strategy in unresectable stage III NSCLC.

Journal: Oncoimmunology

Published: May 16, 2026

Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer (RERUN): Study Protocol for a Real-World, Multicenter, Prospective, Observational Study.

Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer (RERUN): Study Protocol for a Real-World, Multicenter, Prospective, Observational Study.

Journal: Advances in therapy

Published: May 15, 2026

Genomic Profiling, Risk Stratification, and Post-Transformation Treatment Outcomes in Patients with Transformed Small-Cell Lung Cancer: A Multicenter Analysis.

Genomic Profiling, Risk Stratification, and Post-Transformation Treatment Outcomes in Patients with Transformed Small-Cell Lung Cancer: A Multicenter Analysis.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 05, 2026

Clinical efficacy and safety of an overall strategy of immunotherapy combined with chemoradiotherapy for limited-stage small cell lung cancer (including induction ± consolidation ± second-line immunotherapy): A propensity score matching study based on real-world data.

Clinical efficacy and safety of an overall strategy of immunotherapy combined with chemoradiotherapy for limited-stage small cell lung cancer (including induction ± consolidation ± second-line immunotherapy): A propensity score matching study based on real-world data.

Journal: Cancer treatment and research communications

Published: November 10, 2025

Risk stratification model based on estimated dose of radiation to immune cells and radiotherapy-related nadir lymphocyte count for predicting the efficacy of consolidation immunotherapy in stage III non-small cell lung cancer.

Risk stratification model based on estimated dose of radiation to immune cells and radiotherapy-related nadir lymphocyte count for predicting the efficacy of consolidation immunotherapy in stage III non-small cell lung cancer.

Journal: Frontiers in immunology

Published: October 28, 2025

ITHindex: An integrated web-based platform for intratumor heterogeneity evaluation.

ITHindex: An integrated web-based platform for intratumor heterogeneity evaluation.

Journal: PLOS digital health

Published: September 22, 2025

Prognostic significance of CEP55 expression in non-small cell lung cancer: a systematic review and meta-analysis.

Prognostic significance of CEP55 expression in non-small cell lung cancer: a systematic review and meta-analysis.

Journal: BMC pulmonary medicine

Published: September 03, 2025

Microbiota-mediated modulation of radiosensitivity: mechanisms and therapeutic prospects of oral and gut microbiota, metabolites, and probiotics.

Microbiota-mediated modulation of radiosensitivity: mechanisms and therapeutic prospects of oral and gut microbiota, metabolites, and probiotics.

Journal: Frontiers in microbiology

Published: August 21, 2025

Stevens-Johnson syndrome/toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer: A case report.

Stevens-Johnson syndrome/toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer: A case report.

Journal: Medicine

Published: August 17, 2025

Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial.

Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 18, 2025

Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases.

Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases.

Journal: Journal of the National Cancer Center

Published: July 07, 2025

Showing 1-12 of 160

Last Updated: 09/26/2026